New drug KINE-101 passes first safety check in healthy volunteers
NCT ID NCT07324642
First seen Jan 07, 2026 · Last updated Jun 13, 2026 · Updated 29 times
Summary
This early-stage study tested the safety of a new drug, KINE-101, in 24 healthy adults. Participants received daily IV infusions for 7 days at different doses. The main goal was to check for side effects and how the drug moves through the body. No treatment benefit was expected since all volunteers were healthy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, 28644, South Korea
Conditions
Explore the condition pages connected to this study.